title: Involvement of glycation and oxidative stress in diabetic macroangiopathy.
abstract: Under diabetic conditions, the Maillard reaction facilitates the production of reactive oxygen species, and the activity of antioxidant enzymes such as Cu,Zn-superoxide dismutase is decreased, resulting in a remarkable increase of oxidative stress. The oxidative stress attacks DNA, lipids, and proteins and is also thought to be involved in the pathogenesis of diabetic complications, including the progression of macroangiopathy. Proliferation of smooth muscle cells (SMCs) is known to be associated with progression of macroangiopathy and is modulated by several growth factors. At least three mitogens for SMCs, platelet-derived growth factor (PDGF), fibroblast growth factor, and heparin-binding epidermal growth factor-like growth factor (HB-EGF), are known to be produced by SMCs themselves and are considered to be the most potent growth factors in the progression of macroangiopathy as seen in diabetes. HB-EGF, but not PDGF, is regulated at the transcriptional level by 3-deoxyglucosone (3-DG), a major and highly reactive intermediate in the glycation reaction. The induction seems to be triggered by the increase of reactive oxygen species produced by 3-DG. Taken together, glycation reactions under diabetic conditions may be highly associated with the pathogenesis of diabetic macroangiography by enhancing the gene expression of HB-EGF.
authors.affiliation: Department of Biochemistry, Osaka University Medical School, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Taniguchi
authors.forename: H
authors.initials: H
authors.lastname: Kaneto
authors.forename: M
authors.initials: M
authors.lastname: Asahi
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: C
authors.initials: C
authors.lastname: Wenyi
authors.forename: S
authors.initials: S
authors.lastname: Higashiyama
authors.forename: J
authors.initials: J
authors.lastname: Fujii
authors.forename: K
authors.initials: K
authors.lastname: Suzuki
authors.forename: Y
authors.initials: Y
authors.lastname: Kayanoki
mesh_terms: D000818:Animals; D001011:Aorta; D001161:Arteriosclerosis / Q000209:etiology / Q000473:pathology; D004249:DNA Damage; D003847:Deoxyglucose / Q000031:analogs & derivatives / Q000378:metabolism; D003920:Diabetes Mellitus / Q000378:metabolism*; D003925:Diabetic Angiopathies / Q000209:etiology* / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000378:metabolism; D015870:Gene Expression; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D009131:Muscle, Smooth, Vascular / Q000473:pathology; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats
chemical_list: D017127:Glycation End Products, Advanced; C587885:Hbegf protein, rat; D066257:Heparin-binding EGF-like Growth Factor; D036341:Intercellular Signaling Peptides and Proteins; D010982:Platelet-Derived Growth Factor; D012333:RNA, Messenger; D004815:Epidermal Growth Factor; D003847:Deoxyglucose; C016350:3-deoxyglucosone